NovoCure (NVCR) Corporate presentation summary

Product portfolio and technology

• Wearable, non-invasive devices deliver Tumor Treating Fields (TTFields) to treat solid tumors, targeting cancer cell electrical properties while sparing healthy cells.

• Market leader in glioblastoma with expanding indications in non-small cell lung cancer, malignant pleural mesothelioma, and pancreatic cancer.

• Devices include Optune Gio (GBM), Optune Lua (mNSCLC, MPM), and Optune Pax (pancreatic cancer), each with specific indications and safety profiles.

• Devices are portable, with disposable transducer arrays and generator units for patient convenience.

Clinical and commercial performance

• Active patient base for GBM therapy grew 9% year-over-year to 4,464 as of December 2025, with 4% growth in the US and 16% outside the US.

• Positive Phase 3 data support FDA approvals, showing improved median overall survival in GBM, NSCLC, and pancreatic cancer compared to standard therapies.

• Ongoing and upcoming launches include Optune Pax for pancreatic cancer and Optune Mya for brain metastases from NSCLC, pending FDA approval.

• Global expansion of Optune Gio and Optune Lua is planned throughout the year.

Research and development pipeline

• R&D focuses on leveraging TTFields' unique properties to bypass drug delivery barriers and enhance immunotherapy efficacy.

• PANOVA-4 Phase 2 trial in metastatic pancreatic cancer met its primary endpoint with a 74% disease control rate versus 48% historical control.

• TRIDENT Phase 3 trial in newly diagnosed GBM (981 patients) topline data expected Q2 2026; KEYNOTE D58 and LUNAR-2 Phase 3 trials ongoing in GBM and NSCLC.

• Multiple new indication and country launches are anticipated in the near term.